Cooperation of cytokine signaling with chimeric transcription factors in leukemogenesis: PML-retinoic acid receptor alpha blocks growth factor-mediated differentiation.
We utilized a mouse model of acute promyelocytic leukemia (APL) to investigate how aberrant activation of cytokine signaling pathways interacts with chimeric transcription factors to generate acute myeloid leukemia. Expression in mice of the APL-associated fusion, PML-RARA, initially has only modest effects on myelopoiesis. Whereas treatment of control animals with interleukin-3 (IL-3) resulted in expanded myelopoiesis without a block in differentiation, PML-RARA abrogated differentiation that normally characterizes the response to IL-3. Retroviral transduction of bone marrow with an IL-3-expressing retrovirus revealed that IL-3 and promyelocytic leukemia-retinoic acid receptor alpha (PML-RARalpha) combined to generate a lethal leukemia-like syndrome in <21 days. We also observed that a constitutively activated mutant IL-3 receptor, beta(c)V449E, cooperated with PML-RARalpha in leukemogenesis, whereas a different activated mutant, beta(c)I374N, did not. Analysis of additional mutations introduced into beta(c)V449E showed that, although tyrosine phosphorylation of beta(c) is necessary for cooperation, the Src homology 2 domain-containing transforming protein binding site is dispensable. Our results indicate that chimeric transcription factors can block the differentiative effects of growth factors. This combination can be potently leukemogenic, but the particular manner in which these types of mutations interact determines the ability of such combinations to generate acute myeloid leukemia.
Phan
Vernon T
VT
Department of Laboratory Medicine and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA.
Shultz
David B
DB
Truong
Bao-Tran H
BT
Blake
Timothy J
TJ
Brown
Anna L
AL
Gonda
Thomas J
TJ
Le Beau
Michelle M
MM
Kogan
Scott C
SC
D000818:Animals; D001854:Bone Marrow Cells / Q000378:metabolism; D002454:Cell Differentiation; D016207:Cytokines / Q000378:metabolism*; D005434:Flow Cytometry; D016130:Immunophenotyping; D007377:Interleukin-3 / Q000378:metabolism; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000209:etiology / Q000378:metabolism*; D051379:Mice; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D016185:Receptors, Interleukin-3 / Q000378:metabolism; D012190:Retroviridae / Q000235:genetics; D015398:Signal Transduction; D013154:Spleen / Q000166:cytology; D013997:Time Factors; D014443:Tyrosine / Q000378:metabolism; D018909:src Homology Domains
D016207:Cytokines; D007377:Interleukin-3; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D016185:Receptors, Interleukin-3; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014443:Tyrosine